Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime A Davidson

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
BMJ Open Diabetes Research & Care|December 3, 2014
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trialsJaime A Davidson, Rosemarie Lajara, Richard B Aguilar, et al.
Diabetes, Obesity & Metabolism|October 22, 2016
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trialsKatherine R Tuttle, T Dwight McKinney, Jaime A Davidson, et al.
Ethnicity & Disease|April 23, 2016
Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different EthnicityJaime A Davidson, Richard Aguilar, Fernando J Lavalle González, et al.
Postgraduate Medicine|October 31, 2017
Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III programJaime A Davidson, Angela Jones-Leone, Timothy H Wilson, et al.
Postgraduate Medicine|July 9, 2016
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetesGuntram Schernthaner, Fernando J Lavalle-González, Jaime A Davidson, et al.
Ethnicity & Disease|January 8, 2014
Impact of race/ethnicity on efficacy and safety of two starter insulin regimens in patients with type 2 diabetes: a posthoc analysis of the DURABLE trialJaime A Davidson, Bruce H Wolffenbuttel, Richard F Arakaki, et al.
Clinical Therapeutics|March 8, 2006
Postprandial glucose regulation: new data and new implicationsLawrence A Leiter, Antonio Ceriello, Jaime A Davidson, et al.
Clinical Therapeutics|October 8, 2009
Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysisJaime A Davidson, Andreas Liebl, Jens S Christiansen, et al.
Clinical Therapeutics|October 4, 2005
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetesJohn B Buse, Cindy J Rubin, Robert Frederich, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 5, 2010
Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitusJaime A Davidson, Lyndon B Lacaya, Honghua Jiang, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
BMJ Open Diabetes Research & Care|December 3, 2014
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trialsJaime A Davidson, Rosemarie Lajara, Richard B Aguilar, et al.
Diabetes, Obesity & Metabolism|October 22, 2016
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trialsKatherine R Tuttle, T Dwight McKinney, Jaime A Davidson, et al.
Ethnicity & Disease|April 23, 2016
Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different EthnicityJaime A Davidson, Richard Aguilar, Fernando J Lavalle González, et al.
Postgraduate Medicine|October 31, 2017
Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III programJaime A Davidson, Angela Jones-Leone, Timothy H Wilson, et al.
Postgraduate Medicine|July 9, 2016
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetesGuntram Schernthaner, Fernando J Lavalle-González, Jaime A Davidson, et al.
Ethnicity & Disease|January 8, 2014
Impact of race/ethnicity on efficacy and safety of two starter insulin regimens in patients with type 2 diabetes: a posthoc analysis of the DURABLE trialJaime A Davidson, Bruce H Wolffenbuttel, Richard F Arakaki, et al.
Clinical Therapeutics|March 8, 2006
Postprandial glucose regulation: new data and new implicationsLawrence A Leiter, Antonio Ceriello, Jaime A Davidson, et al.
Clinical Therapeutics|October 8, 2009
Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysisJaime A Davidson, Andreas Liebl, Jens S Christiansen, et al.
Clinical Therapeutics|October 4, 2005
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetesJohn B Buse, Cindy J Rubin, Robert Frederich, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 5, 2010
Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitusJaime A Davidson, Lyndon B Lacaya, Honghua Jiang, et al.
Pageof 7